Upcoming Events.


September 27th 2019 - October 1st 2019

Representatives of the company will be attending the conference.

Venue:

www.firabarcelona.com

Fira Gran Via, Barcelona
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat, Spain

October 15th 2019 - October 17th 2019

      

Day 1 – Tuesday, 15th Ocotober/ 2.50 p.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

A soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (pembrolizumab): a new combination in immuno-oncology

Click here for full agenda

Venue: Basel Congress Centre, Basel, Switzerland

November 6th 2019 - November 10th 2019

The company will have presentations at the conference and representatives will be attending.

Venue: 

https://www.nationalharbor.com/gaylord-national/

Gaylord National Hotel & Convention Center in National Harbor, 201 Waterfront St, Forest Heights, MD 20745, USA

Past Events.


June 26th 2019

Immutep to Host Key Opinion Leader Call on Novel Immuno-Oncology Therapy (eftilagimod alpha) in Metastatic Breast Cancer and Other Settings

The call will feature overview presentations by KOLs: Dr. Luc Dirix, MD PhD, from the AZ Sint-Augustinus Hospital in Antwerp, Belgium, and Prof. Salah-Eddin Al-Batran, MD, from the Institute of Clinical Research in Frankfurt, Germany. They will discuss their clinical experience with eftilagimod alpha in AIPAC (metastatic breast cancer) and INSIGHT (exploratory investigator-initiated trial) as well as the current treatment landscape and unmet medical needs, specifically in HER2-negative / HR positive metastatic breast cancer.

Listen to a replay of the Immutep “KOL Call on Novel IO Therapy (eftilagimod alpha)” that took place on Wednesday, June 26, 2019

May 15th 2019 - May 17th 2019

Conference Day 2: Friday 17th May 2019/ 11.25.a.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Combining a soluble LAG-3 protein with an anti-PD-1 antibody in phase I-II trials

Click here for the Presentation at World Advanced Therapies & Regenerative Medicine Congress & Expo 2019

Venue: Business Design Centre, London, UK

May 14th 2019 - May 15th 2019

Frédéric Triebel, CSO & CMO of Immutep, will participate in a panel discussion.

Venue: The New York Academy of Sciences, New York, New York, USA

May 2nd 2019 - May 4th 2019

Venue: Maritim Hotel Berlin, Stauffenbergstrasse 26, 10785 Berlin, Germany

April 2nd 2019 - April 3rd 2019

Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast

The webcast was hosted by Dr. Triebel, Marc Voigt, CEO and Christian Mueller, Director of Clinical Development.

Register: Interested investors can register via a link to the recorded webcast at the following link.

Listen to the related webcast:  Update on Eftilagimod Alpha (IMP321)

Click here for the Presentation related to the webcast

March 29th 2019 - April 3rd 2019

Representatives of the company will be attending the conference

Venue: Georgia World Congress Center, Atlanta, Georgia, USA

March 25th 2019

Immutep to Present IMP761 Preclinical Results in Global Webcast

Speakers: Chief Scientific Officer & Chief Medical Officer, Dr. Frederic Triebel and Executive Director and Chief Executive Officer (CEO) Marc Voigt

Listen to the webcast and view the presentation "Immutep IMP761 Preclinical Results in Autoimmune Disease"

March 6th 2019 - March 9th 2019

Mathieu Angin, Phd, Immutep Research Scientist presents an abstract:

“IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases.”

Session name:         DOP Session 1: Advances in IBD pathophysiology

Session date:           07 March 2019

Session time:           17:30 - 18:30

Session hall:             C1 M1

Venue:  Bella Center, Center Blvd. 5, 2300 Copenhagen, Denmark

March 3rd 2019 - March 5th 2019

Day 2 – Tuesday 5th March/ 3.00 p.m.  

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Two ACTive Immunotherapies (TACTI): Results of a Phase I trial with metastatic melanoma patients

click here for presentation

Venue:  Grand Hyatt, San Diego, USA

February 28th 2019 - March 1st 2019

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.

Venue: SYDNEY InterContinental, 170 Macquarie Street, Sydney; NSW; Australia

February 25th 2019 - February 26th 2019

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.

Venue: BRISBANE Hilton, 190 Elizabeth Street, Brisbane City; QLD; Australia

January 7th 2019 - January 10th 2019

37th Annual J.P. Morgan Health Care Investor Conference

Venue:    San Francisco, California, USA

November 27th 2018 - November 29th 2018

conference day 1/ 02.00 p.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Two ACTIve Immunotherapies (TACTI): Results of Phase I Trial With Metastatic Melanoma Patients (TACTI-mel) Treated With a Soluble LAG-3 Receptor (LAG-3lg or Eftilagimod Alpha) as an Antigen Presenting (APC) Activator Combined with Pembrollzumab

Venue: The Sofitel Berlin Kurfuerstendamm, Berlin, Germany

November 16th 2018
November 8th 2018

Marc Voigt, CEO of Immutep, will present a corporate overview and business update.

Venue: Macquarie Office -  Sydney, Australia

click here for agenda

November 7th 2018 - November 11th 2018

The company will have presentations at the conference and representatives will be attending.

Venue:    Walter E. Washington Convention Center, 801 Mt Vernon Pl NW, Washington, D.C., DC 20001, USA

October 30th 2018

day 2/ 2:55 p.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor
(Eftilagimod Alpha) with Pembrolizumab

click here for agenda / day 2

click here for presentation

Venue:   Basel Congress Center, Basel, Switzerland

October 30th 2018

Marc Voigt, CEO of Immutep, will present a corporate overview and business update.

Venue: Sofitel Melbourne on Collins, Melbourne VIC 3000, Australia

click here to view program of the event

October 24th 2018 - October 27th 2018

Dr. Victoria Atkinson (Principal Investigator TACTI-mel) speaks on the subject:

"Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma."

Venue: Manchester Central Convention Complex, Manchester, United Kingdom

October 19th 2018 - October 23rd 2018

Representatives of the company will be attending the conference.

Venue:   Messe Munich, Messegelände, 81823 Munich, Germany, www.messe-muenchen.de

October 2nd 2018

Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update at 3:30pm ET on Tuesday, October 2, 2018, with one-on-one meetings held throughout the day. The presentation will be webcast live and available for replay via the investor relations section of the company’s website at www.immutep.com.

Listen to the webcast “Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference”

Download "Ladenburg 2018 HC Conference Immutep Presentation"

September 7th 2018

BioCentury 25th Annual NewsMakers - Biotech Industry Conference

Marc Voigt, CEO of Immutep, will present a corporate overview and business update with one-on-one meetings held throughout the day. 

Venue:  Millenium Broadway Hotel & Conference Center, NY, USA

Press release: click here

Download "Newsmaker Immutep Corporate Presentation"

Listen to the webcast “Immutep Newsmakers Presentation” from September 7th, 2018

 

June 20th 2018

 - the largest networking event for life sciences and healthcare industries in the German capital region -

Venue:    Ludwig Erhard Haus, Fasanenstraße 85, Berlin, Germany

June 1st 2018

Immutep to Participate in the Nasdaq Closing Bell Ceremony at the Nasdaq MarketSite in Times Square, New York on June 1st, 2018

June 1st 2018

Immutep to Participate in the Nasdaq Closing Bell Ceremony at the Nasdaq MarketSite in Times Square, New York on June 1st, 2018

May 24th 2018 - May 25th 2018

Frédéric Triebel speaks on the subject:

“Two ACTIve Immunotherapies in melanoma (TACTI-mel): results of a phase I trial with metastatic melanoma patients treated with a soluble LAG-3 receptor (LAG-3Ig or eftilagimod alpha) as an antigen presenting (APC) activator combined with pembrolizumab.”

May 16th 2018 - May 18th 2018
April 18th 2018 - April 19th 2018

Venue:  bbc (Berlin Congress Center), Alexanderstr. 11, 10178, Berlin, Germany

April 14th 2018 - April 18th 2018
April 9th 2018 - April 10th 2018

Company presentation by Jay R. Campbell at 9.00am EDT on Monday, April 9th

Venue:  Essex House, New York, NY, USA

Finance News Network Interview, 12. Nov. 2018, Immutep Limited (ASX:IMM) Executive Director and CEO, Marc Voigt provides an update on the company's clinical trials, collaboration with large pharma and key milestones.

Your Money - Interview with Marc Voigt (CEO), 31.10.2018

Finance News Network - Interview with Marc Voigt (CEO), 06.09.18

FNN – Interview with Immutep

Sky Business News - Interview with Marc Voigt (CEO), 30.04.18

Interview with Frédéric Triebel and Marc Voigt

CNBC - Interview with Marc Voigt (CEO)

Sky Business News - Interview with Marc Voigt (CEO), 25.11.15

The Business - Interview with Lucy Turnbull

Sky Business News - Interview with Marc Voigt (CEO), 16.05.14